Yield10 Bioscience, Inc. (YTENQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0020
0.00 (0.00%)
Jan 31, 2025, 4:00 PM EST
Yield10 Bioscience Revenue
Yield10 Bioscience had revenue of $450.00K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $750.00K, up 190.70% year-over-year. In the year 2023, Yield10 Bioscience had annual revenue of $60.00K, down -86.67%.
Revenue (ttm)
750.00K
Revenue Growth
+190.70%
P/S Ratio
0.00
Revenue / Employee
25.86K
Employees
29
Market Cap
1.47K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.00K | -390.00K | -86.67% |
Dec 31, 2022 | 450.00K | -164.00K | -26.71% |
Dec 31, 2021 | 614.00K | -185.00K | -23.15% |
Dec 31, 2020 | 799.00K | -7.00K | -0.87% |
Dec 31, 2019 | 806.00K | 250.00K | 44.96% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Monarch Cement Company | 270.60M |
Venator Materials | 1.95B |
Rubber Leaf | 10.64M |
Cardinal Ethanol, LLC | 350.34M |
Nanophase Technologies | 47.79M |
Chykingyoung Investment Development Holdings | 305.65K |
Verde Resources | 219.57K |
Yield10 Bioscience News
- 3 months ago - Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals - Accesswire
- 6 months ago - Yield10 Bioscience Announces Second Quarter 2024 Financial Results - GlobeNewsWire
- 7 months ago - Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets - GlobeNewsWire
- 8 months ago - Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina - GlobeNewsWire
- 9 months ago - Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label - GlobeNewsWire
- 9 months ago - Yield10 Bioscience Announces First Quarter 2024 Financial Results - GlobeNewsWire
- 9 months ago - Yield10 Bioscience Announces Delisting from Nasdaq - GlobeNewsWire
- 9 months ago - Yield10 Bioscience Announces 1-for-24 Reverse Stock Split - GlobeNewsWire